흉부 CT에서 우연히 발견된 다발성 낭성 폐병변을 가진 32세 여성
A 32-Year-Old Female with Incidentally Detected Multifocal Cystic Pulmonary Lesions on Chest Computed Tomography
6
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Lymphangioleiomyomatosis (LAM) is a rare condition that exclusively affects women and is characterized by lung parenchymal destruction and the formation of cysts due to infiltration by LAM cells. It can also impact the lymphatic system, leading to the development of fluid-filled cystic structures and abdominal involvement, including renal angiomyolipomas (AML) or lymphangioleiomyoma. LAM can occur sporadically or be associated with tuberous sclerosis complex. Common symptoms include respiratory issues such as dyspnea, pneumothorax, chylothorax, along with other manifestations like renal AML and lymphatic involvement. The diagnosis of LAM relies on a combination of clinical, radiological, and laboratory findings, and treatment options vary depending on symptoms and patient status, with mTOR inhibitors being considered as a treatment option. This case outlines the diagnostic journey and clinical course of a 32-year-old female patient with LAM.
Abstract
Lymphangioleiomyomatosis (LAM) is a rare condition that exclusively affects women and is characterized by lung parenchymal destruction and the formation of cysts due to infiltration by LAM cells. It can also impact the lymphatic system, leading to the development of fluid-filled cystic structures and abdominal involvement, including renal angiomyolipomas (AML) or lymphangioleiomyoma. LAM can occur sporadically or be associated with tuberous sclerosis complex. Common symptoms include respiratory issues such as dyspnea, pneumothorax, chylothorax, along with other manifestations like renal AML and lymphatic involvement. The diagnosis of LAM relies on a combination of clinical, radiological, and laboratory findings, and treatment options vary depending on symptoms and patient status, with mTOR inhibitors being considered as a treatment option. This case outlines the diagnostic journey and clinical course of a 32-year-old female patient with LAM.
참고문헌 (15)
- Gupta N, "Diffuse cystic lung disease. Part I", Am J Respir Crit Care Med, 191, pp.1354~1366 (2015)
- McCormack FX, "Lymphangioleiomyomatosis : calling it what it is : a low-grade, destructive, metastasizing neoplasm", Am J Respir Crit Care Med, 186, pp.1210~1212 (2012)
- Moss J, "Prevalence and clinical characteristics of lymphangioleiomyomatosis(LAM)in patients with tuberous sclerosis complex", Am J Respir Crit Care Med, 164, pp.669~671 (2001)
- Cudzilo CJ, "Lymphangioleiomyomatosis screening in women with tuberous sclerosis", Chest, 144, pp.578~585 (2013)
- Harknett EC, "Use of variability in national and regional data to estimate the prevalence of lymphangioleiomyomatosis", QJM, 104, pp.971~979 (2011)
- Ryu JH, "The NHLBI lymphangioleiomyomatosis registry : characteristics of 230 patients at enrollment", Am J Respir Crit Care Med, 173, pp.105~111 (2006)
- Young L, "Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response : a prospective analysis of the multicenter international lymphangioleiomyomatosis efficacy of sirolimus(MILES)trial", Lancet Respir Med, 1, pp.445~452 (2013)
- Gupta N, "The NHLBI LAM registry : prognostic physiologic and radiologic biomarkers emerge from a 15-year prospective longitudinal analysis", Chest, 155, pp.288~296 (2019)
- Seo JY, "Successful long-term multimodality management of facial lesions in tuberous sclerosis complex in an adult patient", Ann Dermatol, 35(Suppl 2), pp.S243~S246 (2023)
- Hasal E, "Birt-Hogg-Dubé syndrome : diagnostic journey of three cases from skin to gene", Ann Dermatol, 34, pp.66~71 (2022)
- Shin WW, "Birt-Hogg-Dubé syndrome, a rare case in Korea confirmed by genetic analysis", Ann Dermatol, 23(Suppl 2), pp.S193~S196 (2011)
- O'Mahony AM, "Lymphangioleiomyomatosis : a clinical review", Breathe(Sheff), 16, pp.200007~ (2020)
- Gupta N, "Lymphangioleiomyomatosis diagnosis and management : high-resolution chest computed tomography, transbronchial lung biopsy, and pleural disease management. An Official American Thoracic Society", Japanese Respiratory Society clinical practice guideline, 2017, pp.196, 1337~1348
- McCormack FX, "Efficacy and safety of sirolimus in lymphangioleiomyomatosis", N Engl J Med, 364, pp.1595~1606 (2011)
- Gupta N, "Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis", Eur Respir J, 53, pp.1802066~ (2019)